[HTML][HTML] Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer
LM Unterrainer, J Calais… - Annual Review of …, 2024 - annualreviews.org
Prostate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed
by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular …
by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular …
[HTML][HTML] The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective
A Hoffman, GE Amiel - Cancers, 2023 - mdpi.com
Simple Summary Prostate cancer diagnosis and treatment options have rapidly improved
over the last few years. A growing number of publications have moved to front the utilization …
over the last few years. A growing number of publications have moved to front the utilization …
[HTML][HTML] The current landscape of prostate-specific membrane antigen (psma) imaging biomarkers for aggressive prostate cancer
H Al Saffar, DC Chen, C Delgado, J Ingvar, MS Hofman… - Cancers, 2024 - mdpi.com
Simple Summary The review explores the critical role of prostate-specific membrane antigen
(PSMA) PET/CT imaging in diagnosing, staging, and treating prostate cancer. PSMA PET/CT …
(PSMA) PET/CT imaging in diagnosing, staging, and treating prostate cancer. PSMA PET/CT …
[HTML][HTML] Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with …
M Kim, R Seifert, J Fragemann, D Kersting… - European Journal of …, 2023 - Springer
Purpose The aim of this study was to systematically evaluate the effect of thresholding
algorithms used in computer vision for the quantification of prostate-specific membrane …
algorithms used in computer vision for the quantification of prostate-specific membrane …
[HTML][HTML] Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer?
R Laudicella, M Bauckneht, IA Burger - Seminars in Nuclear Medicine, 2023 - Elsevier
While RECIST 1.1 is well established in radiological response assessment, it is of limited
use in prostate cancer (PCa) considering that the disease is often seen only as sclerotic …
use in prostate cancer (PCa) considering that the disease is often seen only as sclerotic …
PSMA PET/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor …
QA Shagera, I Karfis, P Kristanto… - Journal of Nuclear …, 2023 - Soc Nuclear Med
We aimed to evaluate the role of prostate-specific membrane antigen (PSMA) PET/CT for
response assessment and outcome prediction in patients with metastatic castration-resistant …
response assessment and outcome prediction in patients with metastatic castration-resistant …
[HTML][HTML] Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases—A Repeatability Study
M Eveslage, P Rassek, A Riegel, Z Maksoud, J Bauer… - Cancers, 2023 - mdpi.com
Simple Summary Patients with many advanced cancers develop osteoblastic bone
metastases that cannot be assessed by conventional imaging. There is an unmet need for a …
metastases that cannot be assessed by conventional imaging. There is an unmet need for a …
Prostate-specific membrane antigen positron emission tomography as a biomarker to assess treatment response in patients with advanced prostate cancer
B Esen, K Herrmann, S Bavbek, Y Kordan, D Tilki… - European Urology …, 2023 - Elsevier
Context Prostate-specific membrane antigen (PSMA)-targeted positron emission
tomography (PET) has superior accuracy for detection of metastatic lesions in patients with …
tomography (PET) has superior accuracy for detection of metastatic lesions in patients with …
[HTML][HTML] Reawakening of nuclear medicine through molecular imaging: quantitative theranostics and PSMA PET
AC Civelek - Radiology, 2023 - pubs.rsna.org
Dr Civelek is an academic nuclear medicine physician who was previously the deputy
director of nuclear medicine and clinical director at the National Institutes of Health Clinical …
director of nuclear medicine and clinical director at the National Institutes of Health Clinical …
Diagnostic performance of 68Ga-PSMA-11 positron emission tomography/computed tomography to monitor treatment response in patients with metastatic prostate …
B Esen, H Seymen, K Tarim, E Koseoglu… - European Urology …, 2023 - Elsevier
Background Treatment response is traditionally monitored using prostate-specific antigen
(PSA) and conventional imaging in patients with metastatic prostate cancer (mPCa) …
(PSA) and conventional imaging in patients with metastatic prostate cancer (mPCa) …